Impact of Cilostazol Administration on Prevention of Aspiration Pneumonia in Patients With Chronic Limb-Threatening Ischemia

Yosuke Hata; Osamu Iida; Shin Okamoto; Takayuki Ishihara; Kiyonori Nanto; Takuya Tsujimura; Naoko Higashino; Taku Toyoshima; Sho Nakao; Eisaku Ito; Takao Ohki; Toshiaki Mano

doi:10.1253/circrep.CR-24-0052

This article has now been updated. Please use the final version.

Impact of Cilostazol Administration on Prevention of Aspiration Pneumonia in Patients With Chronic Limb-Threatening Ischemia

Yosuke Hata, Osamu Iida , Shin Okamoto, Takayuki Ishihara, Kiyonori Nanto, Takuya Tsujimura, Naoko Higashino, Taku Toyoshima, Sho Nakao, Eisaku Ito, Takao Ohki, Toshiaki Mano

Author information

Keywords: Aspiration pneumonia, Chronic limb-threatening ischemia, Cilostazol

JOURNAL OPEN ACCESS FULL-TEXT HTML Advance online publication

Article ID: CR-24-0052

DOI https://doi.org/10.1253/circrep.CR-24-0052

The final version of this article is now available: Vol. 6 (2024), No. 8 pp. 349-352

Details

Abstract

Background: Cilostazol has reported effectiveness for preventing aspiration pneumonia in patients with ischemic stroke, but whether it is similarly beneficial for patients with chronic limb-threatening ischemia (CLTI) is unclear.

Methods and Results: This retrospective single-center study enrolled 1,368 CLTI patients treated with endovascular therapy (EVT). In the multivariate analysis, predictors for aspiration pneumonia were age (hazard ratio [HR] 1.06 [95% confidence interval (CI) 1.03–1.10]), non-ambulatory status (HR 2.54 [95% CI 1.38–4.65]), the Geriatric Nutritional Risk Index (HR 0.97 [95% CI 0.95–0.99]), and cilostazol (HR 0.37 [95% CI 0.16–0.87]).

Conclusions: Cilostazol administration reduced the risk of aspiration pneumonia in patients with CLTI undergoing EVT.

Corresponding author

Register with J-STAGE for free!